Ultragenyx Pharmaceutical Inc. ( RARE) - Key Metrics
RARE Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $2.10 | -$0.90 | -$0.95 | -$0.96 |
| 2026Q1 | $1.35 | -$1.84 | -$1.96 | -$1.97 |
| 2025Q4 | $2.07 | -$1.29 | -$1 | -$1.01 |
| 2025Q3 | $1.60 | -$1.81 | -$0.92 | -$0.93 |
| 2025Q2 | $1.69 | -$1.17 | -$1.10 | -$0.97 |
RARE Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -9.28 |
| 2026Q1 | 0% | -2.85 |
| 2025Q4 | 0% | -4.46 |
| 2025Q3 | 0% | -4.15 |
| 2025Q2 | 0% | -7.77 |
RARE
Price: $26.49
52 week price:
Payout Ratio Range:
Earnings Per Share: -6.03 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 449700
Ebitda: -96.8 millionMarket Capitalization: 2.6 billion